Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Medico Intercontinental Ltd - 539938 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 With Reference to the above-mentioned subject, we are attaching herewith Secretarial Compliance Report for the year ended 31st March, 2023 given by M/s. Yash Mehta & Associates, Practicing Company Secretaries, Ahmedabad in compliance of Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no - CIR/CFD/CMD1/27/2019 dated February 8, 2019.
13-05-2023
Bigul

Medico Intercontinental Ltd - 539938 - Compliances - 31/03/2023

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/ CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that during the quarter ended March 31, 2023, there was no deviation or variation in the utilization of proceeds of the preferential issue of Equity shares from the objects as stated in the PAS-4. A statement of deviation or variation for the quarter ended March 31, 2023, duly reviewed by the Audit Committee of the Company is enclosed as 'Annexure'. This disclosure will also be hosted on the Company''s website viz. www.medicointercontinental.com
11-05-2023
Bigul

Medico Intercontinental Ltd - 539938 - Compliances - For The Period Ended 31.12.2022

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/ CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that during the quarter ended December 31, 2022, there was no deviation or variation in the utilization of proceeds of the preferential issue of Equity shares from the objects as stated in the PAS-4. A statement of deviation or variation for the quarter ended December 31, 2022, duly reviewed by the Audit Committee of the Company is enclosed as 'Annexure'. This disclosure will also be hosted on the Company''s website viz. www.medicointercontinental.com
19-04-2023
Bigul

Medico Intercontinental Ltd - 539938 - Compliances - Submission Of Compliance Certificate Pursuant To Regulation 40(9) And 40(10) Of The SEBI (Listing Obligation And Disclosure Requirement) Regulation, 2015 For The Year Ended 31St March, 2023.

 We are herewith enclosing Compliance Certificate, pursuant to Regulation 40(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, issued by a Practicing Company Secretary for the year ended 31st March, 2023.
14-04-2023
Bigul

Medico Intercontinental Ltd - 539938 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyMedico Intercontinental Ltd 2CIN NO.L24100GJ1984PLC111413 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 4.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PUNEETA SHARMA Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: mail@medicointercontinental.com Name of the Chief Financial Officer: JAY SHARADKUMAR SHAH Designation: CHIEF FINANCIAL OFFICER EmailId: mail@medicointercontinental.com Date: 08/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
08-04-2023
Bigul

Medico Intercontinental Ltd - 539938 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith the Confirmation Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2023.
05-04-2023
Bigul

Medico Intercontinental Ltd - 539938 - Compliance Certificate For The Financial Year Ended 31St March, 2023.

 I being the Company Secretary of the Company and the Authorized Representatives of the Share Transfer Agents do hereby certify that the M/s MEDICO INTERCONTINENTAL LTD. (Company) has appointed M/s Purva Sharegistry (India) Private Limited as its Share Transfer Agents (STA) for effecting transfer of shares, etc. and is a SEBI Registered Category I Share Transfer Agent bearing Registration No. INR000001112. Further, STA has properly conducted all the activities as prescribed under Regulation 7 (2) of the SEBI (LODR) Regulations, 2015 thereto in relation to both physical and electronic share transfer facility of the Company for the year ended March 31, 2023 on its behalf. In our opinion and to the best of our knowledge and information and according to the documents furnished to us, we here by certify that, the company has complied with the aforesaid regulations and has maintained all the records of the activities in relation to both physical and electronic share transfer of the Company.
05-04-2023
Bigul

Medico Intercontinental Ltd - 539938 - Closure of Trading Window

 Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and in compliance with circular no. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE Limited, we wish to inform you that the 'Trading Window' for dealing in the securities of the Company has been closed and shall remain closed for all the designated persons and their immediate relatives till the conclusion of 48 hours after the declaration of financial results of the company for the quarter and financial year ended March 31, 2023. Accordingly, all designated persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of closure of trading window.
31-03-2023
Bigul

Medico Intercontinental Ltd - 539938 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 We hereby wish to inform you that the unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2022 were approved at the meeting of Board of Directors held on Tuesday, 14th February, 2023. In continuation to the same, the newspaper clipping duly published in English and Gujarati Newspaper is enclosed herewith.
15-02-2023
Bigul

Medico Intercontinental Ltd - 539938 - Statement On Deviation Or Variation Of Funds Raised Though Preferential Issue Of Equity Shares.

 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/ CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that during the quarter ended December 31, 2022, there was no deviation or variation in the utilization of proceeds of the preferential issue of Equity shares from the objects as stated in the PAS-4. A statement of deviation or variation for the quarter ended December 31, 2022, duly reviewed by the Audit Committee of the Company is enclosed as 'Annexure'. This disclosure will also be hosted on the Company''s website viz. www.medicointercontinental.com
14-02-2023
Next Page
Close

Let's Open Free Demat Account